Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, a novel antiviral agent that is in Phase II clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, an oral purine nucleoside prodrug product candidate, which has completed Phase Ia clinical trial for the treatment of dengue; AT-787, a co-formulated, oral, pan-genotypic fixed dose combination of AT-527 and AT-777 that is in Phase I/IIa clinical trial for the treatment of chronic hepatitis C; and AT-889, an investigational, second-generation nucleoside pyrimidine prodrug and other compounds for the treatment of respiratory syncytial virus. It has a Roche License Agreement with F. Hoffmann-La Roche Ltd and Genentech, Inc. for development and commercialization related to AT-527 outside of the United States. The company was incorporated in 2012 and is headquartered in Boston, Massachusetts.
IPO Year: 2020
Exchange: NASDAQ
Website: ateapharma.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/13/2024 | $2.00 → $6.88 | Underweight → Equal-Weight | Morgan Stanley |
| 8/10/2023 | Neutral → Underweight | JP Morgan | |
| 3/2/2022 | $10.00 → $8.00 | Neutral | JP Morgan |
| 3/1/2022 | $10.00 → $9.00 | Market Perform | SVB Leerink |
| 2/16/2022 | $11.00 → $10.00 | Market Perform | SVB Leerink |
| 1/6/2022 | $14.00 → $7.00 | Equal-Weight → Underweight | Morgan Stanley |
| 11/18/2021 | Outperform → Mkt Perform | SVB Leerink | |
| 11/18/2021 | $11.00 | Outperform → Market Perform | SVB Leerink |
| 10/20/2021 | $60.00 → $20.00 | Outperform | SVB Leerink |
| 10/20/2021 | $61.00 → $16.00 | Overweight → Neutral | JP Morgan |
4/A - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)
4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)
8-K - Atea Pharmaceuticals, Inc. (0001593899) (Filer)
SCHEDULE 13D - Atea Pharmaceuticals, Inc. (0001593899) (Subject)
144 - Atea Pharmaceuticals, Inc. (0001593899) (Subject)
EFFECT - Atea Pharmaceuticals, Inc. (0001593899) (Filer)
S-3 - Atea Pharmaceuticals, Inc. (0001593899) (Filer)
10-Q - Atea Pharmaceuticals, Inc. (0001593899) (Filer)
8-K - Atea Pharmaceuticals, Inc. (0001593899) (Filer)
10-Q - Atea Pharmaceuticals, Inc. (0001593899) (Filer)
8-K - Atea Pharmaceuticals, Inc. (0001593899) (Filer)
8-K - Atea Pharmaceuticals, Inc. (0001593899) (Filer)
SC 13G/A - Atea Pharmaceuticals, Inc. (0001593899) (Subject)
SC 13G/A - Atea Pharmaceuticals, Inc. (0001593899) (Subject)
SC 13G/A - Atea Pharmaceuticals, Inc. (0001593899) (Subject)
SC 13G/A - Atea Pharmaceuticals, Inc. (0001593899) (Subject)
SC 13G/A - Atea Pharmaceuticals, Inc. (0001593899) (Subject)
SC 13G/A - Atea Pharmaceuticals, Inc. (0001593899) (Subject)
SC 13G/A - Atea Pharmaceuticals, Inc. (0001593899) (Subject)
SC 13G/A - Atea Pharmaceuticals, Inc. (0001593899) (Subject)
SC 13G/A - Atea Pharmaceuticals, Inc. (0001593899) (Subject)
SC 13G - Atea Pharmaceuticals, Inc. (0001593899) (Subject)
4/A - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)
4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)
4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)
4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)
4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)
4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)
4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)
4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)
4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)
4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)
Global Phase 3 HCV Program Expected to Initiate in 1Q 2025 Potential Best-in-Class Profile of Bemnifosbuvir + Ruzasvir Regimen Supports Opportunity to Disrupt and Expand Global HCV Market of Approximately $3 Billion in Annual Net Sales The Regimen, if Approved, Should Play an Important Role in Efforts to Reduce the Continuing High Disease Burden of HCV BOSTON, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, will outline the Company's strategic priorities for 2025 at the 43rd Annual J.P. Morgan Health
BOSTON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) ("Atea"), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea, will present a business update at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025 at 5:15 p.m. PT in San Francisco, CA. A live webcast of the presentation will be available here and on the Company's website at https://ir.ateapharma.com. An archived webcast will be available on Atea Pharmaceuticals' website for at least 90 days foll
Bradley L. Radoff and Michael Torok, the Managing Director of JEC Capital Partners (together with their affiliates, the "Concerned Shareholder Group" or "we"), who collectively own approximately 3% of the outstanding shares of Atea Pharmaceuticals (NASDAQ:AVIR) ("Atea" or the "Company"), today issued the following open letter to the Company's Board of Directors: *** December 18, 2024 Board of Directors (the "Board") Atea Pharmaceuticals, Inc. 225 Franklin Street, Suite 2100 Boston, MA 02110 Directors, We own approximately 3% of the outstanding shares of Atea, collectively making us one of its largest shareholders. We are writing to express our concerns about the Company's share pr
BOSTON, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it has engaged Evercore, a global independent investment bank, to identify potential opportunities to enhance shareholder value, including the exploration of strategic partnerships related to its Phase 3-ready program for the treatment of hepatitis C virus (HCV). The Company has not set a timetable for the conclusion of its review and has not made any decisions at this time. The Company does not intend to comment further with r
Primary Endpoint Achieved with 98% Sustained Virologic Response at 12 Weeks Post-Treatment (SVR12) after Short Eight Week Treatment Duration Regimen Was Generally Safe and Well-Tolerated Global Phase 3 Program Initiation Expected Early in 2025 BOSTON, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) ("Atea" or "Company"), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that the Company's Phase 2 study of the regimen of bemnifosbuvir, a nucleotide analog polymerase inhibitor, and ruzasvir, an NS5A inhibitor, for treatment of hepatitis C virus (HCV) me
BOSTON, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) ("Atea"), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea Pharmaceuticals, together with other members of the Atea management team, will participate in a fireside chat and present a business update at the 7th Annual Evercore HealthCONx Conference on Wednesday, December 4, 2024 at 9:35 a.m. ET. A live webcast of the presentation will be available here and on the Company's website at https://ir.ateapharma.com/. An archive
BOSTON, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) ("Atea"), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today presented three poster presentations supporting the combination of bemnifosbuvir and ruzasvir as a potential treatment for hepatitis C virus (HCV). The combination of bemnifosbuvir, a nucleotide analog polymerase inhibitor, and ruzasvir, an NS5A inhibitor, is in Phase 2 development for the treatment of HCV. These data are being presented at the American Association for the Study of Liver Diseases' (AASLD) The Liver Meeting 2024, being held from Novembe
Topline SVR12 Results from Global Phase 2 Hepatitis C Virus (HCV) Study (N=275) Expected Q4'24 New Data Supportive of HCV Combination to be Presented at the American Association for the Study of Liver Diseases' (AASLD's) The Liver Meeting 2024 Pharmacokinetic Data for Bemnifosbuvir to be Presented at American College of Pharmacometrics Meeting Conference Call at 4:30 pm ET Today BOSTON, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today reported financial results for the third quarter ended Septem
BOSTON, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) ("Atea"), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it will host a live conference call and audio webcast on Thursday, November 7, 2024, at 4:30 p.m. ET to report financial results for the third quarter ended September 30, 2024, and to provide a business update. To access the live conference call, participants may register here. The live audio webcast of the call will be available under "Events and Presentations" in the Investor Relations section of the Atea Pharmaceuticals website at ir
BOSTON, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) ("Atea"), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced three upcoming poster presentations supporting the combination of bemnifosbuvir and ruzasvir as a potential treatment for Hepatitis C Virus (HCV). The combination of bemnifosbuvir, a nucleotide analog polymerase inhibitor, and ruzasvir, an NS5A inhibitor, is in Phase 2 development for HCV. These data will be presented at the American Association for the Study of Liver Diseases' (AASLD) The Liver Meeting 2024, being held from November 15-19, 2
BOSTON, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company engaged in the discovery and development of oral direct acting therapeutics for severe viral diseases, today announced the appointment of Nancy Gail Berry Agrawal, Ph.D., as Executive Vice President of Preclinical Development. Dr. Agrawal previously served as Vice President of Pharmacokinetics, Pharmacodynamics, and Drug Metabolism at Merck & Co., Inc. "We are delighted to welcome Nancy to the Atea team. Her broad scientific and managerial experience in both drug discovery and drug development spanning across multiple therapeutic areas at Merck, will enrich our scientific and c
BOSTON, June 15, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company engaged in the discovery and development of oral therapeutics for severe viral infections, today announced the appointment of Claudio Avila, MB, BS, Ph.D., as Senior Vice President of Medical Affairs. Dr. Avila previously served as Executive Director, U.S. Medical Strategy and Medical Affairs for COVID-19 at Gilead Sciences. "We are very pleased to welcome Claudio to the Atea team. Claudio's extensive expertise and experience in medical affairs with a focus on COVID-19, hepatitis and HIV as part of his overall interest in serious viral infectious diseases, will complement and s
BOSTON, May 20, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discovery and development of next-generation therapeutics for severe viral infections, today announced the appointment of Jerome Adams, M.D., M.P.H., to its Board of Directors. Dr. Adams most recently served as Surgeon General of the United States and brings a wide range of experience spanning clinical practice, clinical research, public health, and government agency leadership. "We are honored to welcome Dr. Adams to our Board of Directors, as his unique experience as Surgeon General during the COVID-19 pandemic will undoubtedly help guide Atea as we continue to advance our ant
Morgan Stanley upgraded Atea Pharmaceuticals from Underweight to Equal-Weight and set a new price target of $6.88 from $2.00 previously
JP Morgan downgraded Atea Pharmaceuticals from Neutral to Underweight
JP Morgan reiterated coverage of Atea Pharmaceuticals with a rating of Neutral and set a new price target of $8.00 from $10.00 previously
SVB Leerink reiterated coverage of Atea Pharmaceuticals with a rating of Market Perform and set a new price target of $9.00 from $10.00 previously
SVB Leerink reiterated coverage of Atea Pharmaceuticals with a rating of Market Perform and set a new price target of $10.00 from $11.00 previously
Morgan Stanley downgraded Atea Pharmaceuticals from Equal-Weight to Underweight and set a new price target of $7.00 from $14.00 previously
SVB Leerink downgraded Atea Pharmaceuticals from Outperform to Mkt Perform
SVB Leerink downgraded Atea Pharmaceuticals from Outperform to Market Perform and set a new price target of $11.00
SVB Leerink reiterated coverage of Atea Pharmaceuticals with a rating of Outperform and set a new price target of $20.00 from $60.00 previously
JP Morgan downgraded Atea Pharmaceuticals from Overweight to Neutral and set a new price target of $16.00 from $61.00 previously
Topline SVR12 Results from Global Phase 2 Hepatitis C Virus (HCV) Study (N=275) Expected Q4'24 New Data Supportive of HCV Combination to be Presented at the American Association for the Study of Liver Diseases' (AASLD's) The Liver Meeting 2024 Pharmacokinetic Data for Bemnifosbuvir to be Presented at American College of Pharmacometrics Meeting Conference Call at 4:30 pm ET Today BOSTON, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today reported financial results for the third quarter ended Septem
BOSTON, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) ("Atea"), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it will host a live conference call and audio webcast on Thursday, November 7, 2024, at 4:30 p.m. ET to report financial results for the third quarter ended September 30, 2024, and to provide a business update. To access the live conference call, participants may register here. The live audio webcast of the call will be available under "Events and Presentations" in the Investor Relations section of the Atea Pharmaceuticals website at ir
Full Enrollment Achieved in Global Phase 2 Hepatitis C Virus (HCV) Study; Complete SVR12 Results Expected 4Q'24 Bemnifosbuvir and Ruzasvir HCV Data Presented at EASL: Support Best-in-Class Potential with High Antiviral Potency, Low Risk of Drug Interaction, Short Treatment Duration and High Barrier to Resistance Results from COVID-19 Global Phase 3 SUNRISE-3 Trial Expected 2H'24 Conference Call at 4:30 pm ET Today BOSTON, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today reported financial resul
BOSTON, July 31, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) ("Atea"), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it will host a live conference call and audio webcast on Wednesday, August 7, 2024, at 4:30 p.m. ET to report financial results for the second quarter ended June 30, 2024, and to provide a business update. To access the live conference call, participants may register here. The live audio webcast of the call will be available under "Events and Presentations" in the Investor Relations section of the Atea Pharmaceuticals website at ir.atea
Full Enrollment Achieved in Global Phase 3 SUNRISE-3 Trial for Treatment of COVID-19 with Results Expected 2H'24 Global Phase 2 HCV Study On Track to Report Complete SVR12 Results 2H'24 Multiple Presentations Showcasing Preclinical and New Phase 2 Efficacy Data to be Presented at European Association for the Study of the Liver (EASL) Congress 2024 Conference Call at 4:30 pm ET Today BOSTON, May 14, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today reported financial results for the first quarter ended Mar
BOSTON, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) ("Atea"), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it will host a live conference call and audio webcast on Tuesday, May 14, 2024, at 4:30 p.m. ET to report financial results for the first quarter ended March 31, 2024, and to provide a business update. To access the live conference call, participants may register here. The live audio webcast of the call will be available under "Events and Presentations" in the Investor Relations section of the Atea Pharmaceuticals website at ir.at
Final Results Confirm 98% Sustained Virologic Response Rate at Week 4 Post-Treatment (SVR4) from Lead-in Cohort in Phase 2 HCV Study Enrollment in Phase 3 SUNRISE-3 Study Has Surpassed 1,400 COVID-19 Patients in Monotherapy Population; Two Interim Analyses by Independent Data Safety Monitoring Board (DSMB) Planned for 1H'24 with Topline Results Expected 2H'24 Conference Call at 4:30 pm ET Today BOSTON, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today reported financial results for the fourth quar
BOSTON, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) ("Atea"), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it will host a live conference call and audio webcast on Wednesday, February 28, 2024, at 4:30 p.m. ET to report financial results for the fourth quarter and full year ended December 31, 2023, and to provide a business update. To access the live conference call, participants may register here. The live audio webcast of the call will be available under "Events and Presentations" in the Investor Relations section of the Atea Pharmaceutica
Patient enrollment continues in global Phase 3 SUNRISE-3 trial evaluating bemnifosbuvir for COVID-19; first interim analysis expected 1Q24 Phase 2 bemnifosbuvir and ruzasvir combination trial for hepatitis C (HCV) advances, initial results from 60-patient lead-in cohort expected 1Q24 Conference call at 4:30 pm ET today BOSTON, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) ("Atea" or the "Company"), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today reported financial results for the third quarter ended September 30, 2023 and provided a business update. "Promisi
BOSTON, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) ("Atea"), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it will host a live conference call and audio webcast on Wednesday, November 8, 2023, at 4:30 p.m. ET to report financial results for the third quarter ended September 30, 2023, and to provide a business update. To access the live conference call, participants may register here. The live audio webcast of the call will be available under "Events and Presentations" in the Investor Relations section of the Atea Pharmaceuticals website at i